Élan
| Company type | Public |
|---|---|
| NYSE: ELN | |
| Industry | Biotechnology |
| Founded | Athlone, County Westmeath, Ireland (1969) |
| Defunct | 2013 |
| Fate | Acquired by Perrigo |
| Headquarters | Dublin, Ireland |
Key people | Robert Ingram, Chairman Kelly Martin, CEO |
| Products | PRIALT (ziconotide) NANOCRYSTAL technology In pipeline: TYSABRI (natalizumab) AZACTAM (aztreonam for injection, USP) MAXIPIME (cefepime hydrochloride) for Injection |
| Revenue | $0.2 million USD (2012) |
| $(366.9) million USD (2012) | |
| $(363.9) million USD (2012) | |
Elan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the New York Stock Exchange as ELN, the Irish Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC.